Lilly, Boehringer Diabetes Drug Gets European OK

From Associated Press (August 25, 2011)

INDIANAPOLIS -- Drug makers Eli Lilly and Co. and Boehringer Ingelheim said Thursday European regulators have approved their type 2 diabetes treatment Trajenta.

The drug, also known as linagliptin, is sold in the United States under the trade name Tradjenta.

Indianapolis-based Lilly and Boehringer, a German company, said the European Commission granted marketing authorization for 5-milligram tablets to be used alone or in combination with other treatments.

Lilly and Boehringer entered an agreement earlier this year to develop and sell up to five drugs, and Tradjenta is the first of those products. In May, the U.S. Food and Drug Administration approved it to be used as a stand-alone treatment or in combination with other diabetes drugs.

Type 2 is the most common form of diabetes, affecting up to 95 percent of the 24 million people in the U.S. with diabetes. People with the disease have trouble breaking down carbohydrates because their bodies have become resistant to the protein insulin. They are at higher risk for heart attacks, kidney problems, blindness and other serious complications.

Lilly shares fell 41 cents to $35.98 in afternoon trading, as broader indexes dropped about 1 percent.

Lilly, Boehringer diabetes drug gets European OK

From Associated Press (August 25, 2011)

INDIANAPOLIS -- Drug makers Eli Lilly and Co. and Boehringer Ingelheim said Thursday European regulators have approved their type 2 diabetes treatment Trajenta.

The drug, also known as linagliptin, is sold in the United States under the trade name Tradjenta.

Indianapolis-based Lilly and Boehringer, a German company, said the European Commission granted marketing authorization for 5-milligram tablets to be used alone or in combination with other treatments.

Lilly and Boehringer entered an agreement earlier this year to develop and sell up to five drugs, and Tradjenta is the first of those products. In May, the U.S. Food and Drug Administration approved it to be used as a stand-alone treatment or in combination with other diabetes drugs.

Type 2 is the most common form of diabetes, affecting up to 95 percent of the 24 million people in the U.S. with diabetes. People with the disease have trouble breaking down carbohydrates because their bodies have become resistant to the protein insulin. They are at higher risk for heart attacks, kidney problems, blindness and other serious complications.

Lilly shares fell 41 cents to $35.98 in afternoon trading, as broader indexes dropped about 1 percent.


 

Posted: August 2011


View comments

Hide
(web3)